Clinical OMICS

JAN-FEB 2018

Healthcare magazine for research scientists, labs, pathologists, hospitals, cancer centers, physicians and biopharma companies providing news articles, expert interviews and videos about molecular diagnostics in precision medicine

Issue link:

Contents of this Issue


Page 48 of 51 January/February 2018 Clinical OMICs 47 2bPrecise Introduces Pharmacogenomics Data to the Point of Care Precision medicine platform company 2bPrecise,launched in December its phar- macogenomics (PGx) solution, leveraging the clinical decision support capabilities of Translational Software Inc.'s (TSI) PGx data content. "As medicine becomes increasingly personalized, providers are turning to pharmacogenomics as a powerful first step into precision medicine to improve treatment effectiveness," said Bob Robke, vice president of 2bPrecise. "By offering an easy-to-use solution that plugs into existing workflows with minimal effort, an organization can achieve immediate benefits that can then scale to the grow- ing need for additional molecular decision support." 2bPrecise partnered with TSI to leverage its knowledgebase of actively curated, ev- idence-based content, which provides cli- nicians with genotyping prompts; genom- ic decision support; and alerts regarding drug efficacy, toxicity,;and known interac- tions to guide clinical decision making. "What's exciting about our partnership with 2bPrecise is that its technology push- es live, real-time PGx content beyond the lab, directly into the clinical setting. PGx data is no longer limited to a static inter- pretation at the time of result, allowing de- livery of rich genomic insights to clinicians for more precisely diagnosing and treating their patients," added Don Rule, founder and CEO of TSI. n high-resolution digital imaging—a patterned array technology designed to provide sequencing accuracy as well as boost chip utilization and sample density. BGI Genomics, a division of BGI Group, cited new services as one of its priorities when it went public in July, raising RMB 547 million (about $81 million) through an initial public offering. In its IPO prospectus, translated from Chinese via Google Translate, BGI Genomics vowed to "build the world's leading database of life sci- ences." Among its priorities: "Build private cloud data integration plat- form to connect medical information silos." BGI cited high demand for precision medical information com- puting, not only for the sequencing of gene-level data, but also for "medical learning–related data integration, pro- cessing, coupled with a comprehen- sive analysis." "Open(ing) up the genetic database and medicine information database is an important prerequisite for the development of precision medicine," BGI Genomics observed. "An effective way to solve this problem is to create a win-win situation of the platform system, through the company's gene database and platform advantages, integration of other hospital resources, together establish(ing) a precise medi- cal computing environment." Headquartered in Shenzhen, China, BGI Genomics has offices and labora- tories located in major Chinese cities as well as in Europe, North America, and the rest of the Asia–Pacific region. Sanguine is the developer of a mobile health platform designed to link researchers and patients for clinical trials. The company said its direct-to-patient data collection and commercialization platform is cur- rently used by 20 out of the top 40 pharmaceutical companies and more than 15,000 patients. "Selecting the right patient cohort(s) and then recruiting swiftly are the ingredients of a successful clinical trial. The healthcare community has seen time and time again that selecting the wrong patient cohort(s) is a death sen- tence for the trial," Sanguine Chairman Timothy J. Triche M.D., Ph.D., added. —Alex Philippidis LeoWolfert / Getty Images Sturti / Getty Images

Articles in this issue

Links on this page

Archives of this issue

view archives of Clinical OMICS - JAN-FEB 2018